{"success":true,"title":{"id":"352204","title":"Vacunas para SARS-COv-2: entre la urgencia y la ciencia","author":"\u00c1lvarez, Jorgelina","isbn":null,"issn":null,"publisher":"Observatorio de Salud UMaza","publication_year":"2020","resource_url":"","abstract_text":"La crisis de salud p\u00fablica originada por el SARS-CoV-2 ha generado m\u00faltiples consecuencias entre la poblaci\u00f3n, los actores gubernamentales, la ciencia y la salud p\u00fablica en el intento de frenar la pandemia y restablecer un adecuado nivel de vida y salud general y particular. La pandemia por el SARS-Cov-2 ha impuesto un ritmo y velocidad sin precedentes a la investigaci\u00f3n sobre intervenciones diagn\u00f3sticas, terap\u00e9uticas, sociales, econ\u00f3micas, pol\u00edticas y principalmente preventivas, a trav\u00e9s de las vacunas. Las vacunas constituyen la principal estrategia de prevenci\u00f3n de la salud ya que junto a medidas como la sanitizaci\u00f3n del ambiente, el uso de agua potable, la alimentaci\u00f3n han permitido salvar y mejorar las condiciones de vida de la poblaci\u00f3n. Las vacunas son la tecnolog\u00eda sanitaria m\u00e1s costo-efectiva, es decir las que logran el mayor beneficio poblacional de salud en relaci\u00f3n a los costos requeridos y las que mayores logros han permitido obtener a la Salud P\u00fablica.","resource_type":"publication","country":"Europe","language_code":"spa","keywords":"OpenAIRE; Research Graph; publications; Sars-Cov-2; Pandemia; Vacuna; Marco regulatorio; COVID-19; 2;6; reponame:UMaza Digital; instname:Universidad Maza","source_name":"OpenAIRE","kbart_publication_title":null,"kbart_print_identifier":null,"kbart_online_identifier":null,"kbart_title_url":null,"kbart_first_author":null,"kbart_publisher_name":null,"kbart_publication_type":null,"marcxml":null,"created_at":"2026-06-13 11:22:01","updated_at":"2026-06-13 11:22:01","provider_id":"31","collection_id":"36","availability_status":"open_access","access_model":"open_access","regional_availability":null,"subtitle":null,"edition_statement":null,"publication_place":null,"physical_description":null,"pages":null,"doi":"","lcc_code":null,"ddc_code":null,"cdu_code":null,"rda_content_type":null,"rda_media_type":null,"rda_carrier_type":null,"cataloging_status":"metadata_imported","cataloging_notes":null,"cataloging_source":"OpenAIRE","cataloger_name":null,"validated_at":null,"marc_control_number":null,"source_format":"api_json","source_file":null,"marc_leader":null,"url":"","subjects":"Sars-Cov-2; Pandemia; Vacuna; Marco regulatorio; COVID-19","client_id":"1","import_job_id":null,"metadata_quality_score":null,"metadata_quality_level":null,"metadata_quality_checked_at":null,"suggested_language":null,"suggested_subjects":null,"suggested_ddc":null,"suggested_lcc":null,"suggested_cdu":null,"enrichment_status":null,"enrichment_checked_at":null,"marc_source_type":null,"marc_quality_status":null,"marc_is_express":"0","marc_source_note":null,"marc_export_allowed":"0"},"result":{"access":false,"title_id":352204,"institution_id":0,"best":null,"holdings":[],"message":"Sin acceso resuelto. El registro existe, pero no hay holding\/URL activa para abrir el recurso.","openurl":{"genre":"","doi":"","isbn":"","issn":"","title":"","atitle":"","jtitle":"","stitle":"","sid":"","date":"","volume":"","issue":"","spage":"","epage":""}}}